Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: A pooled analysis of data from randomized clinical trials

Epilepsy Research

Volumn 64, Issue 1-2, 2005, Pages 1-11

  Gidal, Barry E ^a   Baltès, Eugène ^b   Otoul, Christian ^b   Perucca, Emilio ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UCB PHARMA   (Belgium)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Antiepileptic drugs; Drug interactions; Levetiracetam; Pharmacokinetics; Serum concentrations

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; VALPROIC ACID; VIGABATRIN;

ARTICLE; BIOEQUIVALENCE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; GEOMETRY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STEADY STATE;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRACETAM; PLACEBOS;

EID: 19444366567     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2005.01.005     Document Type: Article

References (20)

1. E. Ben-Menachem, U. Falter for the European Levetiracetam Study Group Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy Epilepsia 41 2000 1276 1283
2. T. Betts, T. Waegemans, and P. Crawford A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy Seizure 9 2000 80 87
3. T.R. Browne, G.K. Szabo, I.E. Leppik, E. Josephs, J. Paz, E. Baltes, and C.M. Jensen Absence of pharmacokinetic drug interactions of levetiracetam with phenytoin in patients with epilepsy determined by new technique J. Clin. Pharmacol. 40 2000 590 595
4. J.J. Cereghino, V. Biton, B. Abou-Khalil, F. Dreifuss, L.J. Gauer, I. Leppik the United States Levetiracetam Study Group Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial Neurology 55 2000 236 242
5. R. Coupez, J.-M. Nicolas, and T.R. Browne Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid Epilepsia 44 2003 171 178
6. H. Klitgaard, A. Matagne, J. Gobert, and E. Wülfert Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy Eur. J. Pharmacol. 353 1998 191 206
7. R.H. Levy, I. Ragueneau-Majlessi, and E. Baltes Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers Epilepsy Res. 46 2001 93 99
8. Littell, R.C., Milliken, G.A., Stroup, W.W., Wolfinger, R.D., 1996. SAS® System for Mixed Models. SAS Institute Inc., Cary, NC, USA, p. 633.
9. B.A. Lynch, N. Lambeng, K. Nocka, P. Kensel-Hammes, S.M. Bajjalieh, A. Matagne, and B. Fuks The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proc. Natl. Acad. Sci. USA. 101 2004 9861 9866
10. J.-M. Nicolas, P. Collart, B. Gerin, G. Mather, W. Trager, R. Levy, and J. Roba In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic drug Drug Metab. Dispos. 27 1999 250 254
11. P.N. Patsalos Pharmacokinetic profile of levetiracetam: toward ideal characteristics Pharmacol. Ther. 85 2000 77 85
12. P.N. Patsalos, W. Fröscher, F. Pisani, and C.M. van Rijn The importance of drug interactions in epilepsy therapy Epilepsia 43 2002 365 385
13. E. Perucca, B.E. Gidal, and E. Baltès Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials Epilepsy Res. 53 2003 47 56
14. R.A. Radtke Pharmacokinetics of levetiracetam Epilepsia 42 Suppl. 4 2001 24 27
15. I. Ragueneau-Majlessi, R.H. Levy, and C. Meyerhoff Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin Epilepsy Res. 47 2001 55 63
16. I. Ragueneau-Majlessi, R.H. Levy, and F. Janik Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 43 2002 697 702
17. D.J. Schuirmann A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability J. Pharmacokinet. 15 1987 657 680
18. S.D. Shorvon, A. Löwenthal, D. Janz, E. Bielen, P Loiseau for the European Levetiracetam Study Group Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures Epilepsia 41 2000 1179 1186
19. V.W. Steinijans, M. Hartmann, R. Huber, and H.W. Radtke Lack of pharmacokinetic interaction as an equivalence problem Int. J. Clin. Pharmacol. Ther. Toxicol. 29 1991 323 328
20. 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers Eur. J. Clin. Pharmacol. 59 2003 621 630